Skip to main content Skip to journal navigation menu Skip to site footer
contact@ukscip.com
Article

Long-Term Effectiveness of Benralizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-Analysis

Wajan Alqathanin ORCID ,  Hadeel T. Aljaid ,  Raghad A. Alharthi ,  Mastora S. Alotaibi ,  Renad D. Albugami ,  Hawra R. AbuAyfah ORCID ,  Layan W. Alosaimi ORCID ,  Hams M. Aljuaid ,  Bader Abdullah ,  Waleed Alshammari ,  Rashed Mohammed ,  Rahaf Mohammed ,  Ghadah AlAsbi ,  Zanah Abdullah ,  Dalia Zaal

    Received: 30 September 2025; Revised: 8 December 2025; Accepted: 20 December 2025; Published: 29 December 2025

    Abstract

    Benralizumab is an interleukin-5 receptor α-directed monoclonal antibody that depletes eosinophils via antibody-dependent cell-mediated cytotoxicity. This systematic review and meta-analysis evaluated the efficacy and safety of benralizumab in patients with severe eosinophilic asthma (SEA) using evidence from randomized controlled trials, post hoc analyses, and real-world studies. Eight studies comprising 1600 patients were included in this review. Benralizumab significantly reduced the risk of severe exacerbations by 52% (Risk Ratio [RR] = 0.48, 95% confidence interval [CI]: 0.44–0.52) and decreased the maintenance oral corticosteroid (OCS) dose by 11.6 mg/day (95% CI: −13.07 to −10.13). Lung function improved, with a mean increase of 0.22 L in pre-bronchodilator forced expiratory volume in one second (95% CI: 0.18 to 0.26). The asthma control test scores increased by 4.33 points (95% CI: 3.69 to 4.98), surpassing the minimal clinically important difference. These benefits were observed in both randomized controlled trial extensions and real-world studies and were maintained for up to five years, with a favorable safety profile. Subgroup analyses revealed greater improvements in patients with chronic rhinosinusitis with nasal polyps and those receiving maintenance OCS. Benralizumab efficacy was maintained in obese patients, although improvements in lung function were attenuated. These results support the use of benralizumab as a long-term treatment for SEA, particularly in patients with comorbidities or those requiring maintenance OCS. The integration of benralizumab into personalized management plans based on biomarkers and clinical phenotypes can optimize outcomes in SEA.

    Keywords

    References

    1. 1. Cloutier, M.M.; Dixon, A.E.; Krishnan, J.A.; et al. Managing Asthma in Adolescents and Adults: 2020 Asthma Guideline Update From the National Asthma Education and Prevention Program. JAMA 2020, 324, 2301–2317. DOI: https://doi.org/10.1001/jama.2020.21974
    2. 2. Trejo Bittar, H.E.; Yousem, S.A.; Wenzel, S.E. Pathobiology of Severe Asthma. Annu. Rev. Pathol. 2015, 10, 511–545. DOI: https://doi.org/10.1146/annurev-pathol-012414-040343
    3. 3. Agache, I.; Rocha, C.; Beltran, J.; et al. Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab and Omalizumab) for Severe Allergic Asthma: A Systematic Review for the EAACI Guidelines—Recommendations on the Use of Biologicals in Severe Asthma. Allergy 2020, 75, 1043–1057. DOI: https://doi.org/10.1111/all.14235
    4. 4. Ortega, H.G.; Liu, M.C.; Pavord, I.D.; et al. Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. N. Engl. J. Med. 2014, 371, 1198–1207. DOI: https://doi.org/10.1056/NEJMoa1403290
    5. 5. Bel, E.H.; Wenzel, S.E.; Thompson, P.J.; et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N. Engl. J. Med. 2014, 371, 1189–1197. DOI: https://doi.org/10.1056/NEJMoa1403291
    6. 6. Wechsler, M.E.; Scelo, G.; Larenas-Linnemann, D.E.S.; et al. Association Between T2-Related Comorbidities and Effectiveness of Biologics in Severe Asthma. Am. J. Respir. Crit. Care Med. 2024, 209, 262–272. DOI: https://doi.org/10.1164/rccm.202305-0808OC
    7. 7. Djukanović, R.; Brinkman, P.; Kolmert, J.; et al. Biomarker Predictors of Clinical Efficacy of the Anti-IgE Biologic Omalizumab in Severe Asthma in Adults: Results of the SoMOSA Study. Am. J. Respir. Crit. Care Med. 2024, 210, 288–297. DOI: https://doi.org/10.1164/rccm.202310-1730OC
    8. 8. Price, D.; Musgrave, S.D.; Shepstone, L.; et al. Leukotriene Antagonists as First-Line or Add-On Asthma-Controller Therapy. N. Engl. J. Med. 2011, 364, 1695–1707. DOI: https://doi.org/10.1056/NEJMoa1010846
    9. 9. Nair, P. Anti-Interleukin-5 Monoclonal Antibody to Treat Severe Eosinophilic Asthma. N. Engl. J. Med. 2014, 371, 1249–1251. DOI: https://doi.org/10.1056/NEJMe1408614
    10. 10. Lemanske, R.F.; Mauger, D.T.; Sorkness, C.A.; et al. Step-Up Therapy for Children with Uncontrolled Asthma Receiving Inhaled Corticosteroids. N. Engl. J. Med. 2010, 362, 975–985. DOI: https://doi.org/10.1056/NEJMoa1001278
    11. 11. Bousquet, J.; Chanez, P.; Vignola, A.M.; et al. Eosinophil Inflammation in Asthma. Am. J. Respir. Crit. Care Med. 1994, 150, S33–S38. DOI: https://doi.org/10.1164/ajrccm/150.5_Pt_2.S33
    12. 12. Hamelmann, E.; Cieslewicz, G.; Schwarze, J.; et al. Anti-Interleukin 5 but Not Anti-IgE Prevents Airway Inflammation and Airway Hyperresponsiveness. Am. J. Respir. Crit. Care Med. 1999, 160, 934–941. DOI: https://doi.org/10.1164/ajrccm.160.3.9806029
    13. 13. Dorman, S.C.; Efthimiadis, A.; Babirad, I.; et al. Sputum CD34+IL-5Rα+ Cells Increase After Allergen: Evidence for In Situ Eosinophilopoiesis. Am. J. Respir. Crit. Care Med. 2004, 169, 573–577. DOI: https://doi.org/10.1164/rccm.200307-1004OC
    14. 14. Castro, M.; Mathur, S.; Hargreave, F.; et al. Reslizumab for Poorly Controlled, Eosinophilic Asthma: A Randomized, Placebo-Controlled Study. Am. J. Respir. Crit. Care Med. 2011, 184, 1125–1132. DOI: https://doi.org/10.1164/rccm.201103-0396OC
    15. 15. Moran, A.M.; Ramakrishnan, S.; Borg, C.A.; et al. Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma. Am. J. Respir. Crit. Care Med. 2020, 202, 1314–1316. DOI: https://doi.org/10.1164/rccm.202003-0729LE
    16. 16. de Haij, S.; Jansen, J.H.; Boross, P.; et al. In vivo Cytotoxicity of Type I CD20 Antibodies Critically Depends on Fc Receptor ITAM Signaling. Cancer Res. 2010, 70, 3209–3217. DOI: https://doi.org/10.1158/0008-5472.CAN-09-4109
    17. 17. Rothenberg, M.E.; Dellon, E.S.; Collins, M.H.; et al. Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis. N. Engl. J. Med. 2024, 390, 2252–2263. DOI: https://doi.org/10.1056/NEJMoa2313318
    18. 18. Bleecker, E.R.; FitzGerald, J.M.; Chanez, P.; et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 2016, 388, 2115–2127. DOI: https://doi.org/10.1016/S0140-6736(16)31324-1
    19. 19. Nair, P.; Wenzel, S.; Rabe, K.F.; et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. N. Engl. J. Med. 2017, 376, 2448–2458. DOI: https://doi.org/10.1056/NEJMoa1703501
    20. 20. Busse, W.W.; Bleecker, E.R.; FitzGerald, J.M.; et al. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir. Med. 2019, 7, 46–59. DOI: https://doi.org/10.1016/S2213-2600(18)30406-5
    21. 21. Hellings, P.W.; Alobid, I.; Anselmo-Lima, W.T.; et al. EUFOREA/EPOS2020 Statement on the Clinical Considerations for Chronic Rhinosinusitis with Nasal Polyps Care. Allergy 2024, 79, 1123–1133. DOI: https://doi.org/10.1111/all.15982
    22. 22. Lipworth, B.J.; Han, J.K.; Desrosiers, M.; et al. Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps. N. Engl. J. Med. 2025, 392, 1178–1188. DOI: https://doi.org/10.1056/NEJMoa2414482
    23. 23. Çelebi Sözener, Z.; Özdel Öztürk, B.; Şahinoğlu, E.; et al. Benralizumab in severe eosinophilic asthma: A real-life data from Türkiye. Respir. Med. 2025, 248, 108332. DOI: https://doi.org/10.1016/j.rmed.2025.108332
    24. 24. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ 2021, 372, n71. DOI: https://doi.org/10.1136/bmj.n71
    25. 25. Izumo, T.; Tone, M.; Kuse, N.; et al. Effectiveness and Safety of Benralizumab for Severe Asthma in Clinical Practice (J-BEST): A Prospective Study. Ann. Transl. Med. 2020, 8, 438. DOI: https://doi.org/10.21037/atm.2020.04.01
    26. 26. Padilla-Galo, A.; Levy-Abitbol, R.; Olveira, C.; et al. Real-Life Experience with Benralizumab During 6 Months. BMC Pulm. Med. 2020, 20, 184. DOI: https://doi.org/10.1186/s12890-020-01220-9
    27. 27. Numata, T.; Miyagawa, H.; Nishioka, S.; et al. Efficacy of Benralizumab for Patients with Severe Eosinophilic Asthma: A Retrospective, Real-Life Study. BMC Pulm. Med. 2020, 20, 207. DOI: https://doi.org/10.1186/s12890-020-01248-x
    28. 28. Bagnasco, D.; Brussino, L.; Bonavia, M.; et al. Efficacy of Benralizumab in Severe Asthma in Real Life and Focus on Nasal Polyposis. Respir. Med. 2020, 171, 106080. DOI: https://doi.org/10.1016/j.rmed.2020.106080
    29. 29. Korn, S.; Bourdin, A.; Chupp, G.; et al. Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. J. Allergy Clin. Immunol. Pract. 2021, 9, 4381–4392.e4. DOI: https://doi.org/10.1016/j.jaip.2021.07.058
    30. 30. Menzies-Gow, A.; Hoyte, F.L.; Price, D.B.; et al. Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. Adv. Ther. 2022, 39, 2065–2084. DOI: https://doi.org/10.1007/s12325-022-02098-1
    31. 31. Yamaguchi, M.; Nishimura, Y.; Takumi, Y.; et al. Real-World Safety and Effectiveness of Benralizumab in Japanese Patients with Severe Asthma: A Multicenter Prospective Observational Study. J. Asthma Allergy 2024, 17, 45–60. DOI: https://doi.org/10.2147/JAA.S432695
    32. 32. Menzella, F.; Marchi, M.; Caminati, M.; et al. Long-Term Eosinophil Depletion: A Real-World Perspective on the Safety and Durability of Benralizumab Treatment in Severe Eosinophilic Asthma. J. Clin. Med. 2024, 14, 191. DOI: https://doi.org/10.3390/jcm14010191
    33. 33. FitzGerald, J.M.; Bleecker, E.R.; Nair, P.; et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2016, 388, 2128–2141. DOI: https://doi.org/10.1016/S0140-6736(16)31322-8
    34. 34. Laidlaw, T.M.; Buchheit, K.M. Biologics in Chronic Rhinosinusitis with Nasal Polyposis. Ann. Allergy Asthma Immunol. 2020, 124, 326–332. DOI: https://doi.org/10.1016/j.anai.2019.12.001
    35. 35. Toppila-Salmi, S.; Bjermer, L.; Cardell, L.O.; et al. Multi-Disciplinary Expert Perspective on the Management of Type 2 Inflammation-Driven Severe CRSwNP: A Brief Overview of Pathophysiology and Recent Clinical Insights. J. Asthma Allergy 2024, 17, 431–439. DOI: https://doi.org/10.2147/JAA.S447093
    36. 36. Colantuono, S.; Menzella, F.; Mari, P.V.; et al. Patient Response and Remission in Respiratory Disease. J. Int. Med. Res. 2025, 53, 3000605251340894. DOI: https://doi.org/10.1177/03000605251340894
    37. 37. Bonato, M.; Savoia, F.; Orzes, E.; et al. Mepolizumab-Related Blood Eosinophil Decreases Are Associated with Clinical Remission in Severe Asthmatic Patients: A Real-World Study. Antibodies 2025, 14, 61. DOI: https://doi.org/10.3390/antib14030061
    38. 38. Kolbeck, R.; Kozhich, A.; Koike, M.; et al. MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J. Allergy Clin. Immunol. 2010, 125, 1344–1353.e2. DOI: https://doi.org/10.1016/j.jaci.2010.04.004
    39. 39. Laviolette, M.; Gossage, D.L.; Gauvreau, G.; et al. Effects of Benralizumab on Airway Eosinophils in Asthmatic Patients with Sputum Eosinophilia. J. Allergy Clin. Immunol. 2013, 132, 1086–1096.e5. DOI: https://doi.org/10.1016/j.jaci.2013.05.020
    40. 40. Zaazouee, M.S.; Alwarraqi, A.G.; Mohammed, Y.A.; et al. Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis. Front. Pharmacol. 2022, 13, 992731. DOI: https://doi.org/10.3389/fphar.2022.992731
    41. 41. Chastek, B.; Korrer, S.; Nagar, S.P.; et al. Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting. J. Manag. Care Spec. Pharm. 2016, 22, 848–861. DOI: https://doi.org/10.18553/jmcp.2016.22.7.848
    42. 42. Caruso, M.; Morjaria, J.; Emma, R.; et al. Biologic Agents for Severe Asthma Patients: Clinical Perspectives and Implications. Intern. Emerg. Med. 2018, 13, 155–176. DOI: https://doi.org/10.1007/s11739-017-1773-y
    43. 43. Anderson, W.C.; Szefler, S.J. Cost-Effectiveness and Comparative Effectiveness of Biologic Therapy for Asthma. Ann. Allergy Asthma Immunol. 2019, 122, 367–372. DOI: https://doi.org/10.1016/j.anai.2019.01.018
    44. 44. Gonzalez-Uribe, V.; Romero-Tapia, S.J.; Castro-Rodriguez, J.A. Asthma Phenotypes in the Era of Personalized Medicine. J. Clin. Med. 2023, 12, 6207. DOI: https://doi.org/10.3390/jcm12196207
    ×